ArticleEuropean stroke journal2024
Incremental value of serum neurofilament light chain and glial fibrillary acidic protein as blood-based biomarkers for predicting functional outcome in severe acute ischemic stroke.
Article in European stroke journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Diagnostic and prognostic value of blood neurofilament light chain in ischemic stroke: an individual patient data meta-analysis.Journal of neurology · 2026Pooled it
- Clinical Utility of Circulating Biomarkers for Diagnosis and Prognosis of Acute Stroke in the Emergency Department: A Narrative Review from Current Evidence to Clinical Implementation.Diagnostics (Basel, Switzerland) · 2026Review
- Beyond Recanalization: Neurovascular Unit Protection and Precision Adjunctive Therapy for Ischemic Stroke in the Reperfusion Era.Biomolecules · 2026Review
- Blood biomarkers of brain damage in Transient Ischemic Attack: the role of plasma NfL and GFAP.Journal of neurology · 2026Article
- Research Progress of Blood-Based Biomarkers for the Diagnosis and Prognostic Evaluation of Acute Ischemic Stroke.Biomolecules · 2026Review
- Temporal Pattern and Clinical Value of Serum GFAP in Acute Ischemic Stroke: Results from Two Prospective German Cohorts.Translational stroke research · 2026Article
- From Bench to Bedside: Neurofilament Light Chain as a Biomarker in Ischemic Stroke.Current medical science · 2026Review
- Development of a monoclonal antibody-based time-resolved fluorescence immunochromatographic assay strip for rapid and quantitative determination of S100B in serum.Analytical and bioanalytical chemistry · 2026Article
- Association of Blood-Based Biomarkers and Malignant Infarction in Severe Anterior Circulation Ischemic Stroke.Brain and behavior · 2026Article
- Recent advances in stroke biomarkers - implications for prognosis and treatment.Current opinion in neurology · 2026Review
- Seric Molecular Markers Correlated with Stroke Rehabilitation Outcomes: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Association between serum glial fibrillary acidic protein levels and neurological deficit severity in acute ischemic stroke: A cross-sectional study.Surgical neurology international · 2026Article
- Serum levels of neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) in patients with asymptomatic and symptomatic carotid artery stenosis.JVS-vascular science · 2026Article
- The use of brain-specific biomarkers in urine for prediction of neurological outcome and extent of tissue damage following stroke.Scientific reports · 2025Article
- Molecular Mechanisms of the Microbiota-Gut-Brain Axis in the Onset and Progression of Stroke.International journal of molecular sciences · 2025Review
- Systemic S100A8/A9 in patients with moderate to severe acute ischemic stroke: Exploratory analysis of inflammation and functional outcome.Brain, behavior, & immunity - health · 2025Article
- Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders.Molecular neurodegeneration · 2025Article
- From disruption to remodeling: the evolution and therapeutic prospects of Neuroimmune Regulatory Circuitry after ischemic stroke.Frontiers in immunology · 2025Review
- Prognostic serum biomarkers of synaptic, neuronal and glial injury in patients with acute ischemic stroke of the anterior circulation.European journal of neurology · 2025Article
- Extracellular Vesicles from Human Induced Pluripotent Stem Cells Exhibit a Unique MicroRNA and CircRNA Signature.International journal of biological sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBlood-based biomarkers may improve prediction of functional outcome in patients with acute ischemic stroke. The role of neurofilament light chain (NfL) and glial fibrillary acidic (GFAP) as potential biomarkers especially in severe stroke patients is unknown. PATIENTS AND
methodsProspective, monocenter, cohort study including consecutive patients with severe ischemic stroke in the anterior circulation on admission (NIHSS score ⩾ 6 points or indication for mechanical thrombectomy). Outcome was assessed 3 months after the index stroke by the modified Rankin Scale (mRS). Serum biomarkers levels of NfL and GFAP were determined by ultrasensitive ELISA. Univariate and multivariate logistic regression models were performed to determine the association of biomarker levels and functional disability. Discrimination, calibration, and overall performance were analyzed in different models via AUROC, calibration plots (with Emax and Eavg), Brier-score and R2 using variables, identified as important covariates for functional outcome in previous studies.
resultsBetween 06/2020 and 08/2021, 213 patients were included [47% female, mean age 76 (SD ± 12) years, median NIHSS score 13 (interquartile range, IQR 9; 17)]. Biomarker serum levels were measured at a median of 1 [IQR, 1; 2] day after admission. Compared to patients with mRS 0-2 at 3 months, patients with mRS 3-6 had higher serum levels of NfL (median: 136 pg/ml vs 41 pg/ml;
conclusionPrediction of functional outcome after severe acute ischemic stroke was improved by the blood-based biomarkers serum NfL and GFAP, measured in the acute phase of stroke. These findings have to be replicated in independent external cohorts.Study registration: DRKS00022064.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.